{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:27:05Z","timestamp":1758479225226,"version":"3.40.5"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction\/Aims<\/jats:title><jats:p>We aimed to determine whether specific severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV2) vaccines may be associated with acute\u2010onset polyradiculoneuropathy and if they may result in particular clinical presentations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed records of all persons presenting with acute\u2010onset polyradiculoneuropathy from January 1, 2021, to June 30, 2021, admitted to two Neuroscience centers, of the West and North Midlands, United Kingdom. We compared subjects with previous SARS\u2010CoV2 vaccine exposure with a local cohort of persons with acute\u2010onset polyradiculoneuropathy admitted between 2005 and 2019 and compared admission numbers for the studied time frame with that of the previous 3 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 24 persons with acute\u2010onset polyradiculoneuropathy, 16 (66.7%) presented within 4\u2009 weeks after first SARS\u2010CoV2 vaccine. Fourteen had received the AstraZeneca vaccine and one each, the Pfizer and Moderna vaccines. The final diagnosis was Guillain\u2010Barr\u00e9 syndrome (GBS) in 12 and acute\u2010onset chronic inflammatory demyelinating polyneuropathy in 4. Among AstraZeneca vaccine recipients, facial weakness in nine persons (64.3%), bulbar weakness in seven (50%), and the bifacial weakness and distal paresthesias GBS variant in three (21.4%), were more common than in historical controls (<jats:italic>P<\/jats:italic>\u00a0=\u2009.01; <jats:italic>P<\/jats:italic>\u00a0=\u2009.004, and <jats:italic>P<\/jats:italic>\u00a0=\u2009.002, respectively). A 2.6\u2010fold (95% confidence interval: 1.98\u20133.51) increase in admissions for acute\u2010onset polyradiculoneuropathy was noted during the studied time frame, compared to the same period in the previous 3 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Despite a low risk, smaller than that of SARS\u2010CoV2 infection and its complications, exposure to the first dose of AstraZeneca SARS\u2010CoV2 vaccine may be a risk factor for acute\u2010onset polyradiculoneuropathy, characterized by more common cranial nerve involvement.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mus.27461","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T05:27:16Z","timestamp":1637126836000},"page":"233-237","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Acute\u2010onset polyradiculoneuropathy after <scp>SARS\u2010CoV2<\/scp> vaccine in the West and North Midlands, United Kingdom"],"prefix":"10.1002","volume":"65","author":[{"given":"Lay Khoon","family":"Loo","sequence":"first","affiliation":[{"name":"Inflammatory Neuropathy Clinic, Department of Neurology University Hospitals Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Salim","sequence":"additional","affiliation":[{"name":"Department of Neurology Royal Stoke University Hospital, University Hospitals of North Midlands  Stoke\u2010on\u2010Trent UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Neurology Royal Stoke University Hospital, University Hospitals of North Midlands  Stoke\u2010on\u2010Trent UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Neurology Royal Stoke University Hospital, University Hospitals of North Midlands  Stoke\u2010on\u2010Trent UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salini","family":"Sumangala","sequence":"additional","affiliation":[{"name":"Inflammatory Neuropathy Clinic, Department of Neurology University Hospitals Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin S.","family":"Gowda","sequence":"additional","affiliation":[{"name":"Department of Neurology Royal Stoke University Hospital, University Hospitals of North Midlands  Stoke\u2010on\u2010Trent UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Neurology Royal Stoke University Hospital, University Hospitals of North Midlands  Stoke\u2010on\u2010Trent UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-8343","authenticated-orcid":false,"given":"Yusuf A.","family":"Rajabally","sequence":"additional","affiliation":[{"name":"Inflammatory Neuropathy Clinic, Department of Neurology University Hospitals Birmingham  Birmingham UK"},{"name":"Aston Medical School Aston University  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Medicines & Healthcare Regulatory Agency.Coronavirus vaccine\u2010 weekly summary of Yellow Card reporting. Accessed June 30 2021.https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26143"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26144"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242956"},{"key":"e_1_2_10_6_1","article-title":"Exacerbating Guillain\u2010Barre syndrome eight days after vector\u2010based COVID19 vaccination","volume":"2021","author":"Finsterer J","year":"2021","journal-title":"Case Rep Infect Dis"},{"issue":"2","key":"e_1_2_10_7_1","article-title":"Neurological complications of COVID19: Guillain\u2010Barre syndrome following Pfizer COVID\u201019 vaccine","volume":"13","author":"Waheed S","year":"2021","journal-title":"Cureus"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.138"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12455"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307815"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa433"},{"key":"e_1_2_10_12_1","unstructured":"European Medicines Agency.Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5\u20108 July 2021. Accessed July 9 2021.https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-july-2021."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102685"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n295"},{"key":"e_1_2_10_16_1","unstructured":"NHS England.COVID\u201019 vaccination and blood clotting. Information about your vaccination 2021.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/985296\/PHE_12015_COVID"},{"key":"e_1_2_10_17_1","unstructured":"U.S. Food & Drug Administration.Coronavirus (COVID19). Update: July 13 2021.https:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/2e7fe63."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102662"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011881"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011882"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001556\u20107"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.27461","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T05:17:31Z","timestamp":1706591851000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.27461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/mus.27461"],"URL":"https:\/\/doi.org\/10.1002\/mus.27461","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"type":"print","value":"0148-639X"},{"type":"electronic","value":"1097-4598"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"assertion":[{"value":"2021-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}